We are live on ! Find out more
JGC

J. Goldman & Co Portfolio holdings

AUM $3.44B
1-Year Est. Return 33.8%
This Fund
S&P 500
This Quarter Est. Return
+6.67%
1 Year Est. Return
+33.8%
3 Year Est. Return
+89.45%
5 Year Est. Return
+82.14%
10 Year Est. Return
+407.39%
AUM
$844M
AUM Growth
-$811M
Cap. Flow
-$843M
Cap. Flow %
-99.83%
Top 10 Hldgs %
29.6%
Holding
364
New
95
Increased
32
Reduced
43
Closed
187

Top Sells

Rank Stock Value
1
JAH
JARDEN CORPORATION
JAH
+$25M
2
XLNX
Xilinx Inc
XLNX
+$20.1M
3
HSY icon
Hershey
HSY
+$17.2M
4
EL icon
Estee Lauder
EL
+$17M
5
ALTR
Altera Corp
ALTR
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 11.12%
2 Industrials 7.29%
3 Technology 6.69%
4 Communication Services 6.15%
5 Consumer Discretionary 5.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RDUS
126
DELISTED
Radius Health, Inc.
RDUS
$1.7M 0.2%
+43,750
New +$1.04M
CMI icon
127
Cummins
CMI
$89B
$1.66M 0.2%
11,500
-21,500
-65% -$3.04M
NTRS icon
128
Northern Trust
NTRS
$22.2B
$1.65M 0.2%
+24,500
New +$1.63M
ICE icon
129
CALL
Intercontinental Exchange
ICE
$86.3B
$1.62M 0.19%
+37,000
New +$1.59M
AGN
130
CALL
DELISTED
Allergan Inc
AGN
$1.62M 0.19%
7,600
-9,900
-57% -$1.97M
RFP
131
CALL
DELISTED
Resolute Forest Products Inc.
RFP
$1.59M 0.19%
+90,400
New +$1.58M
BEAV
132
CALL
DELISTED
B/E Aerospace Inc
BEAV
$1.53M 0.18%
+26,400
New +$1.47M
IPAS
133
DELISTED
Ipass Inc Common Stock
IPAS
$1.49M 0.18%
109,000
+60,500
+125% +$882K
OLN icon
134
Olin
OLN
$2.47B
$1.49M 0.18%
+65,410
New +$1.59M
RPRX
135
PUT
DELISTED
Repros Therapeutics Inc.
RPRX
$1.42M 0.17%
+142,500
New +$1.22M
KRA
136
DELISTED
Kraton Corporation
KRA
$1.34M 0.16%
+64,271
New +$1.18M
NVGS icon
137
Navigator Holdings
NVGS
$1.35B
$1.32M 0.16%
62,540
-28,000
-31% -$614K
RPRX
138
DELISTED
Repros Therapeutics Inc.
RPRX
$1.26M 0.15%
126,000
+101,000
+404% +$861K
MSTR icon
139
Strategy Inc
MSTR
$35B
$1.22M 0.14%
75,000
-276,930
-79% -$4.38M
X
140
PUT
DELISTED
US Steel
X
$1.17M 0.14%
+43,800
New +$1.46M
CLNY
141
DELISTED
Colony Capital, Inc.
CLNY
$1.16M 0.14%
+48,814
New +$1.14M
MGNI icon
142
Magnite
MGNI
$2.79B
$1.13M 0.13%
70,000
-53,033
-43% -$684K
AGN
143
PUT
DELISTED
Allergan plc
AGN
$1.11M 0.13%
4,300
-4,300
-50% -$1.07M
SFUN
144
DELISTED
Fang Holdings Limited American Depositary Shares (each representing ten Class A Ordinary Shares)
SFUN
$1.1M 0.13%
+2,970
New +$1.31M
LEAF
145
DELISTED
Leaf Group Ltd.
LEAF
$1.09M 0.13%
178,847
-115,250
-39% -$761K
LH icon
146
CALL
Labcorp
LH
$25.8B
$1.05M 0.12%
+11,291
New +$997K
HLT icon
147
Hilton Worldwide
HLT
$73.5B
$1.04M 0.12%
13,333
-188,334
-93% -$14.1M
AUDC icon
148
AudioCodes
AUDC
$250M
$1.03M 0.12%
+226,357
New +$1.05M
USO icon
149
CALL
United States Oil Fund
USO
$2B
$1.02M 0.12%
6,250
-3,125
-33% -$693K
GSAT icon
150
Globalstar
GSAT
$10.2B
$1.01M 0.12%
24,582
-12,043
-33% -$462K

Similar funds

J. Goldman & Co's Q4 2014 Portfolio in Review

As of Q4 2014, J. Goldman & Co held 364 positions worth $844M, down 49% from $1.66B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

J. Goldman & Co withdrew a net $843M in Q4 2014, closing 187 positions and reducing 43 holdings. Its most notable exit was JARDEN CORPORATION, an estimated $25M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 11% of assets, up from 5.6% a quarter earlier, followed by Industrials and Technology.

Against the trend, J. Goldman & Co opened a new position in Wright Medical Group Inc worth $9M.

  • J. Goldman & Co's largest Q4 2014 buy was Wright Medical Group Inc: 335,000 shares worth $9M.
  • J. Goldman & Co added most to Allergan Inc in Q4 2014, an estimated $18.5M increase.
  • J. Goldman & Co's biggest Q4 2014 reduction was Apple, cutting an estimated $14.1M.
  • J. Goldman & Co fully exited JARDEN CORPORATION in Q4 2014, selling an estimated $25M.
  • J. Goldman & Co's ten largest holdings make up 30% of its $844M portfolio in Q4 2014.
  • J. Goldman & Co opened 95 new positions and closed 187 in Q4 2014.
  • J. Goldman & Co's portfolio value fell 49% quarter-over-quarter to $844M.

Based on J. Goldman & Co's 13F filing for Q4 2014, filed 17 Feb 2015.